537 results on '"Seligsohn U"'
Search Results
2. An allosteric disulfide bond is involved in enhanced activation of factor XI by protein disulfide isomerase
3. Abnormal plasma clot structure and stability distinguish bleeding risk in patients with severe factor XI deficiency
4. Type I mutation in the F11 gene is a third ancestral mutation which causes factor XI deficiency in Ashkenazi Jews
5. A mutation in the β3 cytoplasmic tail causes variant Glanzmann thrombasthenia by abrogating transition of αIIbβ3 to an active state
6. Point mutations regarded as missense mutations cause splicing defects in the factor XI gene
7. An αIIb mutation in patients with Glanzmann thrombasthenia located in the N‐terminus of blade 1 of the β‐propeller (Asn2Asp) disrupts a calcium binding site in blade 6
8. An allosteric disulfide bond is involved in enhanced activation of factor XI by protein disulfide isomerase: OR289
9. False‐positive tests for heparin‐induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus
10. Factor XI deficiency in humans
11. Three residues at the interface of factor XI (FXI) monomers augment covalent dimerization of FXI
12. The neurology of cobalamin deficiency in an elderly population in Israel
13. Trp207Gly in platelet glycoprotein Ibα is a novel mutation that disrupts the connection between the leucine‐rich repeat domain and the disulfide loop structure and causes Bernard–Soulier syndrome
14. The type I mutation causing factor XI deficiency in Ashkenazi Jews is a founder mutation of recent Eastern European origin: PA 3.14–3
15. Disulfide bond exchange is required for integrin activation and post-ligation signaling during fibrin clot retraction: PA 3.01–3
16. Factor XI mRNA is spliced upon platelet activation: OC 77.1
17. A mutation in β3 integrin causing macrothrombocytopenia displays constitutive active aIIbβ3 and aVβ3 and proplatelet-like structures on immobilized fibrinogen: OC 34.3
18. Abnormal plasma clot structure and stability distinguish bleeding risk in patients with severe factor XI deficiency: OC 05.5
19. Diversity of Glanzmann thrombasthenia in southern India: 10 novel mutations identified among 15 unrelated patients
20. Treatment of inherited platelet disorders: S-WE-01.1-3
21. FVIIa-CTP and FIX-CTP are novel long-acting coagulation factors with prolonged hemostatic activity in hemophilic animal models: PO-TU-025
22. Inherited platelet disorders
23. Glanzmann thrombasthenia: lessons regarding structure-function relationships: No.18
24. Substitutions of the unique beta3-arg261 have different effects on integrins alphaiib-beta3 and alphav-beta3: OC-TH-042
25. Dimerization of human factor XI is not a prerequisite for its secretion or activation: OC-MO-105
26. Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma
27. Rare bleeding disorders
28. Deciphering the mystery of combined factor V and factor VIII deficiency
29. Problems and complications of treatment in rare bleeding disorders: 26 S 818
30. Combination therapy of low doses of rFVIIa and FEIBA for severe hemophilia A patients with an inhibitor to factor VIII: 14 PO 401
31. Prerequisites for recombinant factor VIIa-induced thrombin generation in plasmas deficient in factors VIII, IX or XI
32. A 13-bp deletion in αIIb gene is a founder mutation that predominates in Palestinian-Arab patients with Glanzmann thrombasthenia
33. A novel Phe171Cys mutation in integrin αIIb causes Glanzmann thrombasthenia by abrogating αIIbβ3 complex formation
34. A common ancestral mutation (C128X) occurring in 11 non‐Jewish families from the UK with factor XI deficiency
35. Thrombophilic factors are not the leading cause of thrombosis in Behçet’s disease
36. Characterization of mutations causing factor VII deficiency in 61 unrelated Israeli patients
37. Severe factor XI deficiency caused by a Gly555 to Glu mutation (factor XI–Glu555): a cross-reactive material positive variant defective in factor IX activation
38. Seven novel mutations in the factor XIII A-subunit gene causing hereditary factor XIII deficiency in 10 unrelated families
39. New observations on factor XI deficiency
40. The prevalence of factor V G1691A but not of prothrombin G20210A and methylenetetrahydrofolate reductase C677T is remarkably low in French Basques
41. Cerebrovascular Events in Patients With Significant Stenosis of the Carotid Artery Are Associated With Hyperhomocysteinemia and Platelet Antigen-1 (Leu33Pro) Polymorphism
42. Inherited factor XI deficiency confers no protection against acute myocardial infarction
43. GLYCOPROTEIN IIIA TRUNCATION RATHER THAN ABSENCE OF CYSTEINE406-CYSTEINE665 BOND CAUSES THROMBASTHENIA IN MOST IRAQI-JEWISH PATIENTS
44. Acquired von Willebrand disease in a patient with angiodysplasia resulting from immune-mediated clearance of von Willebrand factor
45. The Human Platelet αIIb Gene Is Not Closely Linked to Its Integrin Partner β3
46. Fibrin-Dependent Platelet Procoagulant Activity Requires GPIb Receptors and von Willebrand Factor
47. Multiple myeloma: Early vertebral involvement assessed by computerised tomography
48. Characterization of Three Mutations Causing von Willebrand Disease Type IIA in Five Unrelated Families
49. Discerning the ancestry of European Americans in genetic association studies
50. Prevention Program of Type I Glanzmann Thrombasthenia in Israel: Prenatal Diagnosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.